2-[4-(1H-3-pyrazolyl)phenyl]-6-(tributylstannyl)imidazo[1,2-a]pyridine | 938461-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-(1H-3-pyrazolyl)phenyl]-6-(tributylstannyl)imidazo[1,2-a]pyridine
• 英文别名: 2-[4-(1H-3-pyrazolyl)phenyl]-6-(1,1,1-tributylstannyl)imidazo[1,2-a]pyridine；tributyl-[2-[4-(1H-pyrazol-5-yl)phenyl]imidazo[1,2-a]pyridin-6-yl]stannane
• CAS: 938461-48-4
• 化学式: C₂₈H₃₈N₄Sn
• 分子量: 549.347
• InChiKey: TYUMASPGPHLHME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.45
• 重原子数：
  33
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[4-(1H-3-pyrazolyl)phenyl]-6-(tributylstannyl)imidazo[1,2-a]pyridine 、 二碳酸二叔丁酯 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 2-{4-[1-(tert-butoxycarbonyl)-3-pyrazoyl]phenyl}-6-(tributylstannyl)-imidazo[1,2-a]pyridine
  参考文献：
  名称：

  DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION

  摘要：

  公开号：

  EP1956013B1
• 作为产物：
  描述：

  6-iodo-2-[4-(1H-3-pyrazolyl)phenyl]imidazo[1,2-a]pyridine 、 六正丁基二锡 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以42%的产率得到2-[4-(1H-3-pyrazolyl)phenyl]-6-(tributylstannyl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel radioiodinated imidazopyridine derivatives for amyloid-β imaging in Alzheimer’s disease

  摘要：

  Non-invasive detection for amyloid-beta peptide (A beta) deposition has important significance for the early diagnosis and medical intervention for Alzheimer's disease (AD). In this study, we developed a series of imidazopyridine derivatives as potential imaging agents for single-photon emission computed tomography (SPECT). Two of them, compounds DRK092 and DRM106, showed higher affinity for synthetic human A beta 1-40 fibrils than did the well-known amyloid-imaging agent IMPY. A metabolite analysis revealed brain-permeable radioactive metabolites of I-125-labeled DRK092 and IMPY; no radioactive metabolites from I-125-labeled DRM106 ([I-125]DRM106) were detected. In addition, in vitro autoradiography clearly demonstrated specific binding of [I-125]DRM106 in the hippocampal region of AD enriched with A beta plaques. Thus, our results strongly suggested that compound DRM106 can be used as an imaging agent for SPECT to detect A beta deposition in AD brain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.05.043